Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 November 2004, Vol. 104, No. 9, pp. 2697-2703.
Prepublished online as a Blood First Edition Paper on July 15, 2004; DOI 10.1182/blood-2003-10-3717.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-10-3717v1
104/9/2697    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chandrashekran, A.
Right arrow Articles by Casimir, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chandrashekran, A.
Right arrow Articles by Casimir, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted October 31, 2003
Accepted May 12, 2004

Targeted retroviral transduction of kit+ hematopoietic cells using novel ligand-display technology

Anil Chandrashekran, Myrtle Y Gordon, and Colin Casimir*

Faculty of Medicine, Department of Haematology, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom

* Corresponding author; email: c.casimir{at}imperial.ac.uk.

Gene therapy for a wide variety of disorders would be greatly enhanced by the development of vectors that could be targeted for gene delivery to specific populations of cells. We describe here high efficiency targeted transduction based on a novel targeting strategy that exploits the ability of retroviruses to incorporate host cell proteins into the surface of the viral particle as they bud through the plasma membrane. Ecotropic retroviral particles produced in cells engineered to express the membrane-bound form of stem cell factor (mbSCF) transduce both human cell lines and primary cells with high efficiency in a strictly c-kit (SCF-receptor) dependent fashion. The availability of efficient targeted vectors provides a platform for the development of a new generation of therapies employing in vivo gene delivery.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
E. Verhoeyen, M. Wiznerowicz, D. Olivier, B. Izac, D. Trono, A. Dubart-Kupperschmitt, and F.-L. Cosset
Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells
Blood, November 15, 2005; 106(10): 3386 - 3395.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
L. Chan, D. Nesbeth, T. MacKey, J. Galea-Lauri, J. Gaken, F. Martin, M. Collins, G. Mufti, F. Farzaneh, and D. Darling
Conjugation of Lentivirus to Paramagnetic Particles via Nonviral Proteins Allows Efficient Concentration and Infection of Primary Acute Myeloid Leukemia Cells
J. Virol., October 15, 2005; 79(20): 13190 - 13194.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020